Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial.

ABSTRACT:

Background

Sildenafil is the drug of choice for neonatal pulmonary hypertension in developing countries where inhaled nitric oxide is not available. Available as oral and intravenous preparation - no study has been done in the past to compare the two forms. Each has its own benefits - but requires comparison in terms of efficacy and safety. This study was done to compare the efficacy of oral versus intravenous (IV) sildenafil in infants with mild to moderate pulmonary hypertension.

Methods

An open labelled randomized trial was conducted in a neonatal intensive care unit of urban tertiary hospital in western India between February 2019 to December 2020. Infants born after 34 weeks of gestation with Pulmonary arterial pressure (PAP) > 25 mm Hg measured by echocardiography, wit

SUBMITTER: Chetan C 

PROVIDER: S-EPMC9137149 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature